20 reports of this reaction
2.1% of all CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE reports
#8 most reported adverse reaction
RASH is the #8 most commonly reported adverse reaction for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, manufactured by Actavis Pharma, Inc.. There are 20 FDA adverse event reports linking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE to RASH. This represents approximately 2.1% of all 933 adverse event reports for this drug.
Patients taking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 20 FDA reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.1% of all adverse event reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, making it a notable side effect.
If you experience rash while taking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.